Laronidase (Aldurazyme TM) Enzyme Replacement Therapy With Hematopoietic Stem Cell Transplant for Hurler Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01572636|
Recruitment Status : Terminated (Research Cancelled)
First Posted : April 6, 2012
Last Update Posted : September 27, 2018
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment|
|Mucopolysaccharidosis Type IH MPS I Hurler Syndrome||Drug: Laronidase|
|Study Type :||Observational|
|Actual Enrollment :||20 participants|
|Official Title:||MT2011-21C Laronidase (Aldurazyme TM) Enzyme Replacement Therapy (ERT) With Hematopoietic Stem Cell Transplantation (HSCT) for Hurler Syndrome (MPS IH).|
|Actual Study Start Date :||March 28, 2012|
|Actual Primary Completion Date :||May 1, 2018|
|Actual Study Completion Date :||May 1, 2018|
Laronidase use in Hurler Syndrome
Laronidase receiving prior and post transplant
Administered 0.58 mg/kg/dose intravenously (IV) once a week beginning 12 weeks before planned hematopoietic stem cell transplant (HSCT) and resume same dosing regimen for 8 weeks after HSCT.
Other Name: Aldurazyme
- Overall Survival [ Time Frame: At 1 Year ]Patients alive at 1 year post transplantation.
- Incidence of Engraftment [ Time Frame: 1 Year Post Transplant ]The incidence of donor engraftment will be estimated by taking the simple proportion of patients achieving donor engraftment over the number of evaluable patients. Donor engraftment will be defined as achieving an absolute neutrophil count ≥ 5x10^8/kg for three consecutive days before day 42 and maintenance of >10% donor chimerism through one year post transplant or death.
- Incidence of Grade III-IV Acute Graft Versus Host Disease [ Time Frame: Day 100 ]Cumulative incidence will be used to estimate grade III-IV acute GvHD, treating death as a competing risk.
- Proportion of patients in need of ventilator support [ Time Frame: 1 Year ]Count of patients using ventilator by 1 year.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||Child, Adult, Older Adult|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Probability Sample|
- Diagnosis of mucopolysaccharidosis type IH (MPS I, Hurler syndrome) and being considered as a candidate for first transplant according to a University of Minnesota myeloablative hematopoietic stem cell transplant (HSCT) protocol
- No prior therapy with laronidase enzyme replacement therapy (ERT)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01572636
|United States, Minnesota|
|Masonic Cancer Center, University of Minnesota|
|Minneapolis, Minnesota, United States, 55455|
|Principal Investigator:||Paul Orchard, M.D.||Masonic Cancer Center, University of Minnesota|
|Responsible Party:||Masonic Cancer Center, University of Minnesota|
|Other Study ID Numbers:||
MT2011-21C ( Other Identifier: Blood and Marrow Transplant Program )
|First Posted:||April 6, 2012 Key Record Dates|
|Last Update Posted:||September 27, 2018|
|Last Verified:||September 2018|
Carbohydrate Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lysosomal Storage Diseases
Connective Tissue Diseases